Economic Burden in a German Cohort of Patients with Multiple Sclerosis

Cost of disorders of the brain in Europe 2010

(2011) Anders Gustavsson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

(2010) V. Devonshire et al.   EUROPEAN JOURNAL OF NEUROLOGY

Economic Burden of Multiple Sclerosis

(2010) Huseyin Naci et al.   PHARMACOECONOMICS

Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis

(2009) N. Putzki et al.   EUROPEAN JOURNAL OF NEUROLOGY

Multiple sclerosis beyond EDSS: depression and fatigue

(2009) Tjalf Ziemssen   JOURNAL OF THE NEUROLOGICAL SCIENCES

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

(2009) Roisín Lonergan et al.   Multiple Sclerosis Journal

Direkte Kosten der Parkinson-Behandlung

(2009) R. Ehret et al.   NERVENARZT

Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

(2009) Paul Tappenden et al.   VALUE IN HEALTH

The cost effectiveness and budget impact of natalizumab for formulary inclusion

(2009) Justin Bakhshai et al.   JOURNAL OF MEDICAL ECONOMICS

Multiple Sclerosis in the UK

(2008) Paul McCrone et al.   PHARMACOECONOMICS

Assessing health-related quality of life in patients with restless legs syndrome

(2008) Svenja Happe et al.   SLEEP MEDICINE

German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus

(2008) J.-Matthias Graf von der Schulenburg et al.   VALUE IN HEALTH

Psychological aspects of multiple sclerosis

(2007) Maria José Sá   CLINICAL NEUROLOGY AND NEUROSURGERY